Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant

1 Department of Experimental Virology, Institute of Sera and Vaccines, Korunni 108, 101 03 Prague, Czechoslovakia and 2 Institute of Organic Chemistry and Biochemistry, Flemingovo nám. 2, 106 02 Prague, Czechoslovakia Several vaccinia virus (VV)-varicella-zoster virus (VZV) recombinants expressing g...

Full description

Saved in:
Bibliographic Details
Published in:Journal of general virology 1991-06, Vol.72 (6), p.1445-1449
Main Authors: Ludvikova, Viera, Kunke, David, Hamsikova, Eva, Kutinova, Luda, Vonka, Vladimir
Format: Article
Language:English
Subjects:
Animals
Antibodies, Viral - analysis
Antibody Formation
Cell Line
DNA, Viral - genetics
Enzyme-Linked Immunosorbent Assay
Herpesvirus 3, Human - genetics
Herpesvirus 3, Human - immunology
Humans
Mice
Neutralization Tests
Plasmids
Rats
Recombinant Proteins - immunology
Vaccines, Synthetic
vaccinia virus
Vaccinia virus - genetics
Vaccinia virus - immunology
varicella-zoster virus
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viral Vaccines
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:1 Department of Experimental Virology, Institute of Sera and Vaccines, Korunni 108, 101 03 Prague, Czechoslovakia and 2 Institute of Organic Chemistry and Biochemistry, Flemingovo nám. 2, 106 02 Prague, Czechoslovakia Several vaccinia virus (VV)-varicella-zoster virus (VZV) recombinants expressing glycoprotein I (gpI) of VZV were isolated from the Prague strain of VV. One of these, v46, was inoculated intraperitoneally into mice. Groups of mice were bled 4 and 8 weeks later and their sera were examined for anti-VZV and anti-VV antibodies by ELISA. At 4 weeks, all mice inoculated with the three largest virus doses (10 7 , 10 6 and 10 5 p.f.u.), and at 8 weeks all mice inoculated with the four highest virus doses (10 7 , 10 6 , 10 5 and 10 4 p.f.u.), had developed both anti-VV and anti-VZV antibodies. Antibodies were also detected in a high proportion of mice infected with lower doses of virus and in some instances VZV antibodies were present in the absence of VV antibodies. None of the animals inoculated in parallel with either a thymidine kinase-negative mutant of the original VV or diluent alone developed antibody reactive with VZV. The specificity of the reaction was assessed further by Western blotting using anti-gpI monoclonal antibodies as a positive control. Sera from animals immunized with v46 possessed antibody capable of neutralizing extracellular VZV in the presence of complement. Received 24 May 1990; accepted 6 March 1991.
ISSN:0022-1317
1465-2099
DOI:10.1099/0022-1317-72-6-1445